^
    Back
    Association details:
    Biomarker:HER-2 underexpression
    Cancer:Breast Cancer
    Drug:albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) +
    cyclophosphamide (Alkylating agent) +
    epirubicin (Topoisomerase II inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Nanomedicine
    Title:

    Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer

    Published date:
    03/06/2023
    Excerpt:
    A total of 430 patients receiving 2-weekly dose-dense epirubicin and cyclophosphamide (EC) followed by 2-weekly paclitaxel (Sb-P, Lps-P, or Nab-P)...In HER2-low-positive patients, the pathological complete response (pCR) rate in Nab-P group was significantly higher than that in the other three paclitaxel groups...The NST regimen containing Nab-P could be considered a promising treatment option in HER2-low-positive breast cancer.
    DOI:
    10.1016/j.nano.2023.102666